Skip to content
Company Analysis

Nyxoah SA NYXH

A comprehensive view of key metrics, scores, and financial health for Nyxoah SA

Overview of Nyxoah S.A.

NYXH NGM
Healthcare Medical Instruments & Supplies Framework: Medical Devices & Diagnostics Micro Cap
Nyxoah S.A. (NYXH), is a Micro Cap company, in the Medical Instruments & Supplies industry, last closed at $1.39, about 0.0% overvalued vs fair value, -82.1% 1Y return, ranked 1072/1122 in sector.
USD 1.39
-6.71%
(Delayed)
• Vol 90d: 136.4%
52-Week Range
Market Cap
$67.40M
Enterprise Value
$76.00M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 88%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.nyxoah.com
HQ Mont-Saint-Guibert
Employees 183
Fiscal year Dec 31

Next Events

Earnings Aug 5

Fair Value Snapshot

Bear Base Bull
$-1
$-1
$-1
Current: $1.39

Engine Room Money Flow™

Micro Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$4.5M
4%%
Gross Profit
$3.0M
10.3%%
Operating Income (GAAP)
$-58.8M
-30.4%%
EBITDA
$-52.8M
-25.5%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
65.7%
Excellent

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Nyxoah SA's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
39
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
63
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 87% Coverage
Trade-Off Triangle Visualization A ternary plot showing NYXH's balance between Growth (40.2%), Profitability (24.4%), and Safety (35.4%). Growth 40% Safety 35% Profitability 24%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

49th percentile vs peers
49
Key Signals
Revenue CAGR 3Y 74.4% 91p Rev Growth YoY 4.0% 44p EPS Growth YoY -17.1% 25p Asset Growth YoY 27.6% 91p TSR -80.2% 4p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (74.4%, 91th percentile)
Risks

No significant risks identified for this axis.

Profitability

29th percentile vs peers
30
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

43th percentile vs peers
43
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Nyxoah SA.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-1.49
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000